Angiogenic therapy for Chronic Ischemic Myocardium with Platelet-derived Endothelial Cell Growth Factor Gene in aDog Model

血管生成是一种很有前途的新治疗策略，为严重缺血性心脏和周围血管疾病患者提供新的血流场所，这些患者不适合标准的血运重建策略。血小板来源的内皮细胞生长因子（PD-ECGF）也与胸腺嘧啶磷酸化酶（TP）相同，催化胸腺嘧啶可逆磷酸化分解为胸腺嘧啶和2'-脱氧-d -核糖-1-磷酸。PD-ECGFfTP已被证明在缺氧诱导的细胞凋亡中具有血管生成活性并具有抵抗能力。本研究考察了编码人全长PD-ECGF/TP互补DNA的哺乳动物表达质粒载体在犬慢性缺血心肌中的表达效果。我们发现，注射PD-ECGF/TP基因不仅能诱导血管生成，改善心肌功能，还能抑制心肌细胞的凋亡。血小板来源的内皮细胞生长因子可能是基因治疗血管生成的重要候选基因。

Angiogenesis is a promising novel therapeutic strategy to provide new venues for blood flow in patients with severe ischemic heart arid peripheral vascular disease, who are not candidates for standard revascularization strategies.Platelet-derived endothelial cell gro\yth factor (PD-ECGF) is also identical to thymidine phosphorylase (TP), catalyze the reversible phosphorolysis of thymidine to thymine and 2'-deoxy-D-ribose-1-phosphate. PD-ECGFfTP has been shown to possess angiogenic activity in and confers resistance to apoptosis induced by hypoxia.This study examine the effectiveness of delivery a mammalian expression plasmid vector encoding human full length PD-ECGF/TP complementary DNA in the chronic canine ischemic myocardium. We found that injecting of PD-ECGF/TP gene not only induced angiogenesis, myocardiac function improvement, but also inhibited the apoptosis of the myocardial cells. The platelet-derived endothelial cell growth factor may be a influential candidate gene for gene therapeutic angibgenesis.